Bio-link Australia Pty. Ltd.

19th September 2017 – Oncology Venture: Early data from ongoing LiPlaCis® Ph1/2 study show response and clinical benefits in hard to treat patients with metastatic Breast Cancer

Bio-Link’s client Oncology Venture has released promising early data from the ongoing LiPlaCis® Phase 1/2 study in hard to treat patients with metastatic Breast Cancer, reporting treatment response and clinical benefits. Patients were selected as likely responders using a proprietary Drug Response Predictor (DRPTM) technology. Read more here.